Healius Limited (HLS) AI Stock Analysis

• Market Cap: €635.37M
• Dividend Yield: N/A
• Average Volume (3M): 2.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: -23.02%
• EPS Growth: 33.11%
• Country: AU
• Employees: 4,329
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.02
• Shares Outstanding: 726,132,800
• 10 Day Avg. Volume: 3,249,015
• 30 Day Avg. Volume: 2,941,962
• PEG Ratio: 0.05
• Price to Book (P/B): 0.26
• Price to Sales (P/S): 0.11
• P/FCF Ratio: 0.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.78
• Price Target Upside: -9.85% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$1.00 ▲(16.28% Upside)

Healius Limited's overall stock score is primarily impacted by its financial performance and valuation. The company faces significant financial challenges, including declining revenues and high leverage, which are reflected in its low financial performance score. The valuation is also weak due to a negative P/E ratio and lack of dividend yield. Technical analysis provides some neutral signals, but they are not enough to offset the financial and valuation concerns.

Healius Limited Business Overview & Revenue Model

Company Description

Healius Limited (HLS) is a prominent healthcare company based in Australia, primarily focused on delivering pathology and diagnostic services. The company operates in the healthcare sector, providing a range of medical testing services, including pathology, radiology, and other laboratory services. Healius aims to improve patient care by offering timely and accurate diagnostic information, thereby supporting healthcare professionals in their decision-making processes.

How the Company Makes Money

Healius generates revenue primarily through its pathology and diagnostic services, which are offered to both individual patients and healthcare providers. The company operates a network of pathology laboratories and collection centers across Australia, allowing it to capture a significant share of the market for diagnostic testing. Key revenue streams include fees charged for medical tests, consultations, and specialized services such as genetic testing and imaging. Additionally, Healius has established partnerships with various healthcare providers and government entities, which further contribute to its earnings by expanding its service reach and ensuring a steady flow of patients. The company may also benefit from economies of scale as it consolidates its operations and invests in technology to enhance service efficiency and reduce costs.

Healius Limited Financial Statement Overview

Summary

Healius Limited faces significant financial challenges, with declining revenues, negative profitability, and high leverage. The income statement reflects substantial losses, while the balance sheet shows high debt levels. Cash flow generation remains a relative strength, providing some liquidity cushion. The company needs to address its profitability and leverage issues to improve its financial health and stability.

Income Statement

Healius Limited's income statement reveals significant challenges. The company experienced a notable revenue decline of 13.8% in the most recent year, coupled with a negative net profit margin of -11.2%, indicating substantial losses. The gross profit margin has also decreased significantly from previous years, reflecting reduced profitability. Despite these challenges, there is a slight improvement in EBIT margin, but overall, the income statement highlights a need for strategic improvements to return to profitability.

Balance Sheet

The balance sheet of Healius Limited shows a high debt-to-equity ratio of 1.55, indicating significant leverage, which could pose financial risks. The return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. However, the equity ratio remains relatively stable, suggesting that the company still maintains a reasonable level of equity compared to its total assets. Overall, the balance sheet indicates financial strain but also potential for stabilization.

Cash Flow

Healius Limited's cash flow statement presents mixed results. The operating cash flow to net income ratio is relatively strong, indicating good cash generation relative to net income. However, the free cash flow has declined by 20.84%, and the free cash flow to net income ratio suggests that cash generation is not sufficient to cover losses. Despite these challenges, the company maintains a positive operating cash flow, which is a positive sign for liquidity management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.34B	1.34B	1.75B	1.71B	2.29B	1.90B
Gross Profit	398.60M	398.60M	1.52B	341.70M	779.20M	526.50M
EBITDA	92.10M	31.20M	-298.10M	-57.80M	734.80M	470.40M
Net Income	-151.20M	-151.20M	-645.80M	-367.80M	307.90M	43.70M
Balance Sheet
Total Assets	1.78B	1.78B	2.98B	3.65B	4.14B	3.78B
Cash, Cash Equivalents and Short-Term Investments	57.20M	57.20M	60.10M	115.30M	81.30M	70.10M
Total Debt	911.80M	911.80M	1.60B	1.77B	1.78B	1.44B
Total Liabilities	1.19B	1.19B	1.94B	2.15B	2.22B	1.92B
Stockholders Equity	587.90M	587.90M	1.04B	1.51B	1.92B	1.86B
Cash Flow
Free Cash Flow	223.00M	231.70M	173.80M	230.30M	480.30M	432.00M
Operating Cash Flow	277.00M	285.70M	266.80M	306.40M	573.80M	493.30M
Investing Cash Flow	730.00M	730.00M	-63.00M	67.30M	-401.70M	386.90M
Financing Cash Flow	-995.60M	-1.02B	-259.00M	-339.70M	-163.50M	-984.70M

Healius Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HLS, the sentiment is Positive. The current price of 0.86 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.80, and below the 200-day MA of 0.89, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 59.56 is Neutral, neither overbought nor oversold. The STOCH value of 71.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HLS.

Healius Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	69 Neutral	AU$524.72M	15.63	18.59%	4.79%	6.73%	37.16%
MVF	68 Neutral	AU$268.85M	10.75	10.25%	7.61%	6.65%	―
SHL	64 Neutral	AU$10.27B	19.43	6.32%	5.15%	9.44%	-0.37%
IDX	55 Neutral	AU$977.07M	172.37	0.94%	2.56%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	48 Neutral	€635.37M	-1.21	-67.21%	―	-23.02%	33.11%
GSS	48 Neutral	AU$72.68M	-3.54	-36.16%	―	62.81%	16.37%

Healius Limited Corporate Events

Healius Limited Announces Key Leadership Appointments

Healius Limited has announced the appointment of Andrew Thomson as the new Chief Financial Officer, succeeding Steve Humphries who is retiring. Thomson brings extensive experience from his previous roles in multinational businesses, which is expected to aid Healius in executing its T27 strategic plan. Additionally, Eric Swayn has been appointed as the National Laboratory Operations Manager, bringing over 25 years of experience in the Australian pathology industry. These appointments are anticipated to strengthen Healius’s operational leadership and support its strategic objectives.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Announces Director Change

Healius Limited announced that Michael Stanford has ceased to be a director as of September 30, 2025. The announcement details his holdings, which include 40,000 ordinary shares directly and an indirect interest in 32,468 ordinary shares held by Mrs. Sally Stanford. This change in directorship may impact the company’s governance and strategic direction.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Strengthens Leadership with New Director Appointment

Healius Limited announced the appointment of Christopher Hall as a director, effective from September 30, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team, which could potentially enhance its market position and operational capabilities in the healthcare sector.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Announces Hybrid 2025 AGM for Enhanced Shareholder Engagement

Healius Limited has announced that its 2025 Annual General Meeting will be held on October 30, 2025, as a hybrid event, allowing shareholders to participate either in person or virtually. This approach aims to enhance shareholder engagement and accessibility, reflecting Healius’s commitment to transparency and stakeholder involvement.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Announces Strategic Board Changes

Healius Limited announced significant changes to its Board of Directors with the resignation of Dr. Michael Stanford and Mr. Neil Vinson, and the appointment of Mr. Steven Rubic and Mr. Chris Hall as new Non-Executive Directors. These appointments bring extensive experience in healthcare and asset management, aligning with Healius’ strategic goals and ensuring a diverse and skilled board to oversee the company’s T27 strategy, which is crucial for its future growth and market positioning.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Releases 2025 Corporate Governance Statement

Healius Limited has released its corporate governance statement for the financial year ending June 30, 2025. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. This disclosure is part of Healius’s commitment to transparency and accountability in its operations, potentially enhancing stakeholder trust and reinforcing its market position.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Reinforces Commitment to Corporate Governance in 2025 Statement

Healius Limited has released its 2025 Corporate Governance Statement, highlighting its commitment to high standards of corporate governance in alignment with ASX Recommendations. The statement outlines the company’s governance framework, emphasizing ethical conduct and social responsibility, with the Board and its committees overseeing various aspects such as risk management and remuneration.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Announces Cessation of Performance Rights

Healius Limited announced the cessation of 616,606 performance rights due to the lapse of conditional rights that were not met. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s performance metrics and future financial planning.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Citigroup Ceases Substantial Holding in Healius Limited

Healius Limited has announced that Citigroup Global Markets Australia Pty Limited and its related corporate bodies have ceased to be substantial holders in the company as of September 1, 2025. This change in substantial holding involves several transactions, including a decrease in relevant interest by Citibank, N.A. Sydney Branch and Citigroup Global Markets Limited, and an increase by Citigroup Global Markets Australia Pty Limited and Citigroup Global Markets Inc. These changes reflect adjustments in securities lending agreements and standard market transactions, potentially impacting the company’s shareholder structure and market perception.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Director Increases Shareholding, Signaling Confidence

Healius Limited announced a change in the director’s interest, with Director John Mattick acquiring 200,000 ordinary shares through on-market trades. This acquisition reflects a significant increase in Mattick’s holdings, potentially indicating confidence in the company’s future performance and stability, which could positively influence stakeholder perceptions.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Director Acquires Shares, Indicating Confidence in Company

Healius Limited announced a change in the director’s interest, with Neil Vinson acquiring 17,045 ordinary shares at an average price of $0.88 per share through an on-market trade. This acquisition reflects a strategic move by the director, potentially signaling confidence in the company’s future performance and stability, which may influence stakeholder perceptions positively.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Releases FY 2025 Full-Year Results

Healius Limited has released its full-year results for FY 2025, highlighting the company’s financial performance and business prospects. The announcement includes insights into potential risks and uncertainties that could impact future results, such as regulatory decisions, competitive changes, and cost fluctuations, which are crucial for stakeholders to consider.

The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.71 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Reports FY25 Results with Revenue Growth and Strategic Shifts

Healius Limited reported a 5.7% increase in group revenue to $1.34 billion for FY25, with underlying EBITDA at $239.3 million and EBIT at $17.1 million, aligning with market expectations. The company has sold Lumus Imaging, resulting in a debt-free balance sheet, and is focusing on revenue diversification and cost reduction, including a $15-20 million cut in support costs. Pathology revenues grew by 6.0% despite challenges such as Tropical Cyclone Alfred, while Agilex Biolabs faced a 3.3% revenue decline due to geopolitical issues but expects recovery in FY26.

The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.71 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Updates Securities Trading Policy to Prevent Insider Trading

Healius Limited, a company listed on the Australian Securities Exchange, has revised its Policy on Trading in Healius Securities. This update aims to minimize the risk of insider trading and protect the company’s reputation by setting specific restrictions for employees and additional restrictions for directors and key management personnel. The updated policy aligns with ASX Listing Rule 12.12 and industry practices, ensuring compliance and maintaining investor confidence.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.